ImmuCell (NASDAQ:ICCC) Share Price Passes Above 200 Day Moving Average – Time to Sell?

ImmuCell Co. (NASDAQ:ICCC)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.44 and traded as high as $4.93. ImmuCell shares last traded at $4.85, with a volume of 12,836 shares changing hands.

ImmuCell Stock Up 2.5 %

The company has a quick ratio of 1.44, a current ratio of 3.11 and a debt-to-equity ratio of 0.36. The company has a 50-day moving average of $5.13 and a two-hundred day moving average of $4.45. The company has a market capitalization of $43.67 million, a P/E ratio of -9.80 and a beta of 0.62.

ImmuCell (NASDAQ:ICCC) last issued its earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share for the quarter. The business had revenue of $7.75 million during the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Mesirow Financial Investment Management Inc. increased its holdings in ImmuCell by 100.0% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 12,178 shares during the period. Citadel Advisors LLC purchased a new stake in ImmuCell during the fourth quarter valued at approximately $149,000. Northern Trust Corp boosted its position in shares of ImmuCell by 51.0% in the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 14,982 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of ImmuCell by 13.9% during the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after acquiring an additional 7,878 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new position in ImmuCell during the 4th quarter valued at approximately $676,000. Institutional investors own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.